Development Level

Tbio 18 | 11,445
Tchem 3 | 1,598
Tclin 3 | 613

Collection

Kinase: IDG Consortium (Target... 1 | 125

IMPC Phenotype

increased circulating triglyce... 2 | 42
decreased circulating glucose ... 1 | 126
increased circulating sodium l... 1 | 71
preweaning lethality, complete... 1 | 979
preweaning lethality, incomple... 1 | 499
tremors 1 | 39

Disease

Carcinoma 20 | 11,493
glioblastoma 15 | 5,792
osteosarcoma 14 | 7,950
lung carcinoma 12 | 2,843
ovarian cancer 12 | 8,520
Cancer 11 | 2,499
Astrocytoma, Pilocytic 10 | 3,081
cystic fibrosis 10 | 1,696
lung adenocarcinoma 10 | 2,716
lung cancer 10 | 4,740
malignant mesothelioma 10 | 3,232
non-small cell lung cancer 10 | 2,890
psoriasis 10 | 6,694
Breast cancer 9 | 3,578
adult high grade glioma 9 | 3,801
ependymoma 9 | 4,679
invasive ductal carcinoma 9 | 2,951
atypical teratoid / rhabdoid tumor 8 | 5,112
intraductal papillary-mucinous neoplasm (IPMN) 8 | 3,291
pancreatic cancer 8 | 2,398
tuberculosis 8 | 2,010
ulcerative colitis 8 | 1,819
interstitial cystitis 7 | 2,312
medulloblastoma, large-cell 7 | 6,241
oligodendroglioma 7 | 2,850
primary pancreatic ductal adenocarcinoma 7 | 1,109
Kidney cancer 6 | 2,613
colon cancer 6 | 1,478
group 3 medulloblastoma 6 | 4,104
primitive neuroectodermal tumor 6 | 3,035
Autosomal recessive predisposition 5 | 1,442
Gliosis 5 | 56
astrocytic glioma 5 | 2,597
intraductal papillary-mucinous carcinoma (IPMC) 5 | 2,989
subependymal giant cell astrocytoma 5 | 2,287
Endometriosis 4 | 540
Rheumatoid arthritis 4 | 1,191
acute quadriplegic myopathy 4 | 1,158
astrocytoma 4 | 1,146
intraductal papillary-mucinous adenoma (IPMA) 4 | 2,955
medulloblastoma 4 | 720
non-small cell lung carcinoma 4 | 317
pituitary cancer 4 | 1,972
Arthritis 3 | 290
Carcinoma, Squamous Cell 3 | 110
Colon carcinoma in situ 3 | 9
Liver cancer 3 | 604
Mental Depression 3 | 333
Muscle hypotonia 3 | 571
Prenatal onset 3 | 139
Prostatic Neoplasms 3 | 495
Proteinuria 3 | 144
Schizophrenia 3 | 1,160
Squamous cell carcinoma 3 | 129
breast carcinoma 3 | 1,638
dermatomyositis 3 | 966
diabetes mellitus 3 | 1,728
ductal carcinoma in situ 3 | 1,745
esophageal adenocarcinoma 3 | 737
gastric carcinoma 3 | 807
hereditary spastic paraplegia 3 | 318
pediatric high grade glioma 3 | 1,064
posterior fossa group A ependymoma 3 | 468
Alzheimer's disease 2 | 658
Attention deficit hyperactivity disorder 2 | 278
Autistic Disorder 2 | 364
Bell Palsy 2 | 58
Bipolar Disorder 2 | 666
Cerebrovascular disease 2 | 238
Colonic Neoplasms 2 | 142
Coronary artery disease 2 | 268
Duchenne muscular dystrophy 2 | 601
Facial Paresis 2 | 59
Facial muscle weakness of muscles innervated by CN VII 2 | 58
Highly variable clinical phenotype 2 | 150
Highly variable phenotype and severity 2 | 150
Highly variable phenotype, even within families 2 | 150
Hypersensitivity reaction type II disease 2 | 253
Kidney disease 2 | 430
Liver Cirrhosis, Experimental 2 | 769
Motor delay 2 | 147
Multiple Sclerosis 2 | 540
Neoplasm Invasiveness 2 | 161
No development of motor milestones 2 | 147
Phenotypic variability 2 | 150
Pick disease 2 | 1,894
RENAL ADYSPLASIA 2 | 25
Renal dysplasia 2 | 28
Stomach Neoplasms 2 | 300
Strabismus 2 | 270
Vascular disease 2 | 319
aldosterone-producing adenoma 2 | 665
chronic rhinosinusitis 2 | 512
fibroadenoma 2 | 559
glioblastoma multiforme 2 | 142
head and neck cancer 2 | 271
juvenile dermatomyositis 2 | 1,187
nasopharyngeal carcinoma 2 | 1,058
pancreatic carcinoma 2 | 562
progressive supranuclear palsy 2 | 676

Tissue

Blood and immune system 24 | 16,909
Digestive Tract 24 | 17,369
Endocrine System 24 | 18,159
Female tissues 24 | 17,400
Liver and Pancreas 24 | 16,750
Male tissues 24 | 17,142
Nervous System 24 | 16,725
Respiratory system 24 | 16,393
Skin and soft tissues 24 | 17,230
Urinary Tract 24 | 16,678
Cardiovascular System 23 | 15,192

Target Family

Non-IDG 20 | 12,091
Enzyme 3 | 4,145
Kinase 1 | 634

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 24 | 24
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Integrin alpha-11 ITGA11 Tbio Non-IDG -1.13736 14.3 76
Plexin-D1 PLXND1 Tbio Non-IDG -1.64721 46.3 171
IQ motif and SEC7 domain-containing protein 1 IQSEC1 Tbio Non-IDG -1.04789 14.7 28
Integrin alpha-7 ITGA7 Tbio Non-IDG -1.63563 42.4 193
Integrin alpha-8 ITGA8 Tbio Non-IDG -1.36974 22.0 145
Integrin alpha-4 ITGA4 Tclin Non-IDG -2.53262 310.4 1312
Ras-related protein R-Ras RRAS Tbio Enzyme -2.15870 149.8 150
Integrin alpha-10 ITGA10 Tbio Non-IDG -0.86801 7.54 15
Integrin alpha-5 ITGA5 Tbio Non-IDG -2.29130 169.1 826
Phosphatidylinositol 4-phosphate 5-kinase type-1 beta PIP5K1B Tbio Kinase -1.07498 11.3 96